Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 868.00K | 2.27M | 1.38M | 375.00K | 0.00 | 0.00 |
Gross Profit | -1.32M | 123.00K | 120.00K | 355.00K | -297.00K | -188.00K |
EBITDA | -39.24M | -44.16M | -165.42M | -157.38M | -107.00M | -81.98M |
Net Income | -50.95M | -59.60M | -179.05M | -165.76M | -106.63M | -82.01M |
Balance Sheet | ||||||
Total Assets | 25.79M | 38.34M | 73.70M | 205.85M | 239.44M | 219.94M |
Cash, Cash Equivalents and Short-Term Investments | 17.43M | 29.85M | 65.22M | 193.72M | 232.97M | 213.12M |
Total Debt | 108.69M | 102.95M | 101.38M | 94.16M | 1.40M | 1.64M |
Total Liabilities | 133.46M | 131.44M | 130.21M | 129.08M | 17.77M | 13.24M |
Stockholders Equity | -107.67M | -93.10M | -56.51M | 76.78M | 221.67M | 206.70M |
Cash Flow | ||||||
Free Cash Flow | -55.77M | -72.03M | -155.03M | -135.48M | -82.60M | -66.67M |
Operating Cash Flow | -55.77M | -72.03M | -155.01M | -135.34M | -82.15M | -66.35M |
Investing Cash Flow | 0.00 | 0.00 | -20.00K | -139.00K | -445.00K | -316.00K |
Financing Cash Flow | 18.07M | 36.66M | 26.52M | 96.24M | 102.45M | 247.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.92B | -0.43 | -41.69% | 2.21% | 22.29% | -1.85% | |
41 Neutral | $47.13M | ― | -175.12% | ― | ― | 23.17% | |
38 Underperform | $19.56M | ― | -53.42% | ― | ― | 18.73% | |
38 Underperform | $11.44M | ― | -105.79% | ― | -82.54% | -12.53% | |
37 Underperform | $55.32M | ― | 82.91% | ― | -63.88% | 77.72% | |
36 Underperform | $15.26M | ― | -103.80% | ― | ― | 47.99% | |
28 Underperform | $11.76M | 0.11 | 1224.29% | ― | 1184.51% | ― |
On January 15, 2025, BioXcel Therapeutics increased its Board of Directors from seven to eight members by appointing Dr. Rajiv Patni as a Class II director. Dr. Patni brings extensive experience in global product development within the biopharmaceutical sector and is expected to contribute significant value to the company’s strategic direction.